AIM
OVID icon

Aigen Investment Management’s Ovid Therapeutics OVID Stock Holding History

Aigen Investment Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,966
Closed -$155K – 1046
2020
Q2 		$155K Buy
+20,966
New +$98.1K 0.02% 733

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Aigen Investment Management's OVID Position: Q3 2020 in Review

Aigen Investment Management sold out of Ovid Therapeutics (OVID) in Q3 2020, closing a stake of 20,966 shares — an estimated $155K sold.

Aigen Investment Management first reported a position in OVID in Q2 2020 and held it in 1 quarter. The position peaked at $155K in Q2 2020. 91 funds tracked by Wall St. Rank hold OVID as of Q3 2020.

  • Aigen Investment Management reported no remaining Ovid Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Aigen Investment Management sold 20,966 Ovid Therapeutics shares in Q3 2020, an estimated $155K.
  • Aigen Investment Management first reported a position in Ovid Therapeutics in Q2 2020 and held it in 1 quarter.
  • Aigen Investment Management's Ovid Therapeutics position peaked at $155K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2020.

Based on Aigen Investment Management's 13F filing for Q3 2020, filed 6 Nov 2020.